



Contact: Jenn Snider
Phone: +1 (814) 234-1919 x126
Email: jenn@indigobiosciences.com

FOR IMMEDIATE RELEASE

INDIGO Biosciences Expands Oncology-Focused Preclinical Testing Portfolio

Expansion Includes New Growth Factor Receptor and Transcription Factor Assays Targeting Preclinical Oncology Research

State College, PA (5 January 2021) – INDIGO Biosciences, the recognized industry leader in nuclear receptor research, has expanded their robust testing portfolio to include five new assays used primarily for preclinical oncology research. These cell-based *in vitro* assays include four new growth factor assays and a transcription factor pathway assay and provide discovery researchers with the ability to quickly make critical decisions about potential drug candidates before moving into trials. In addition to their significance in oncology, these receptors play important roles in research surrounding cardiovascular disease and wound healing.

“INDIGO is committed to consistently offering discovery scientists new ways to move their research forward faster,” says Dr. Jack Vanden Heuvel, Chief Scientific Officer of INDIGO. “The addition of these growth factor and transcription factor assays is a natural extension of our existing platform, and the reliable results and rapid turnaround of both our kits and screening services gives researchers the means to make critical decisions confidently.”

Growth factor receptors are the first step in a cell’s signaling cascade for differentiation and proliferation. These growth or survival signals then bind to cell surface receptors known as receptor tyrosine kinases (RTKs) along multiple different pathways. While growth factors act on different cell types, their signal pathways often overlap, and this shared mechanism has generated a significant amount of interest in cancer research.

In cancer cells, the growth factor and transcription factor signaling may mutate to never turn on or off, or to be overexpressed, leading to uncontrolled growth and replication of the cancerous cells. To fight these various cancers, oncology researchers are constantly exploring new small molecule combinations that can act as potential angiogenesis inhibitors, cancer growth inhibitors, and monoclonal antibodies that target growth factor receptors.

In vitro assays, such as those offered by INDIGO, provide important early indications of a compound or antibody’s potential for progressing to further development and clinical testing. INDIGO’s assays allow researchers to definitively determine what receptors are affected to ensure the selectivity of target compounds, a key piece of information necessary to proceed with development. The new offerings from INDIGO include four growth factor assays: Epidermal Growth Factor Receptor 1 (EGFR1), Growth Hormone Receptor (GHR), Transforming Human Growth Factor Beta Receptor I/II (TGFβR), and Vascular

Endothelial Growth Factor Receptor 2 (VEGFR2), as well as one new transcription factor assay: TEAD4/YAP (Hippo). Each is available both as a screening service or as an all-inclusive kit.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. is a leading provider of nuclear receptor and *in vitro* toxicology solutions that accelerate scientific decision-making. INDIGO supplements the world's largest portfolio of nuclear receptor kits and services and *in vitro* toxicology solutions with greater results readability, reproducibility, and faster turnaround times. Our solutions, plus supportive team and reliable science and platforms aim to reduce the time, cost, and risk associated with the discovery process. Learn more at www.indigobiosciences.com.